JP4680894B2 - 安定化させた煙霧剤分散体 - Google Patents

安定化させた煙霧剤分散体 Download PDF

Info

Publication number
JP4680894B2
JP4680894B2 JP2006509816A JP2006509816A JP4680894B2 JP 4680894 B2 JP4680894 B2 JP 4680894B2 JP 2006509816 A JP2006509816 A JP 2006509816A JP 2006509816 A JP2006509816 A JP 2006509816A JP 4680894 B2 JP4680894 B2 JP 4680894B2
Authority
JP
Japan
Prior art keywords
dispersion
nanoparticles
drug
continuous phase
propellant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006509816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526624A (ja
JP2006526624A5 (enExample
Inventor
アール．ジュニア バラン，ジミー
ジェイ． ガブリオ，ブライアン
エス． ステフェリー，ジェイムズ
ダブリュ． スタイン，スティーブン
イー． ウッド，トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of JP2006526624A publication Critical patent/JP2006526624A/ja
Publication of JP2006526624A5 publication Critical patent/JP2006526624A5/ja
Application granted granted Critical
Publication of JP4680894B2 publication Critical patent/JP4680894B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0095—Preparation of aerosols
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
    • C09K23/017—Mixtures of compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
    • C09K23/38—Alcohols, e.g. oxidation products of paraffins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006509816A 2003-05-30 2004-04-08 安定化させた煙霧剤分散体 Expired - Fee Related JP4680894B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/449,443 US7459146B2 (en) 2003-05-30 2003-05-30 Stabilized aerosol dispersions
PCT/US2004/010847 WO2004108118A1 (en) 2003-05-30 2004-04-08 Stabilized aerosol dispersions

Publications (3)

Publication Number Publication Date
JP2006526624A JP2006526624A (ja) 2006-11-24
JP2006526624A5 JP2006526624A5 (enExample) 2007-05-24
JP4680894B2 true JP4680894B2 (ja) 2011-05-11

Family

ID=33451787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509816A Expired - Fee Related JP4680894B2 (ja) 2003-05-30 2004-04-08 安定化させた煙霧剤分散体

Country Status (6)

Country Link
US (1) US7459146B2 (enExample)
EP (1) EP1628645A1 (enExample)
JP (1) JP4680894B2 (enExample)
KR (1) KR20060038938A (enExample)
CN (1) CN1798549B (enExample)
WO (1) WO2004108118A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US7109247B2 (en) * 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US20040242729A1 (en) * 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
DE102004053310A1 (de) * 2004-11-04 2006-05-11 Wacker Chemie Ag Mikrowellenaktive Siliconelastomere
EP1700825A1 (de) * 2004-12-23 2006-09-13 Degussa AG Oberflächenmodifizierte, strukturmodifizierte Titandioxide
CN101243130B (zh) * 2005-08-05 2011-12-07 3M创新有限公司 显示具有改善的流动性的组合物
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US20070292688A1 (en) * 2005-08-18 2007-12-20 Eastman Kodak Company Silylamine modified nanoparticulate carriers
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
US7767736B2 (en) * 2005-12-05 2010-08-03 3M Innovative Properties Company Flame retardant polymer composition
DE102006000691A1 (de) * 2006-01-02 2007-07-05 Henkel Kgaa Aerosol-Reiniger mit korrosionsinhibierender Wirkung
US20100119697A1 (en) * 2006-05-10 2010-05-13 3M Innovative Properties Company Compositions and coatings containing fluorescent, inorganic nanoparticles
CN101108166B (zh) * 2006-07-19 2011-07-27 鲁明华 定量纳米气雾剂及其制备方法
JP5401989B2 (ja) * 2007-01-16 2014-01-29 住友ベークライト株式会社 医療用粒子、及び分析用粒子、並びにそれらの製造方法
DE102007008663A1 (de) * 2007-02-20 2008-08-21 Merck Patent Gmbh Bindemittel
EP2137533A2 (en) * 2007-04-19 2009-12-30 3M Innovative Properties Company Uses of water-dispersible silica nanoparticles for attaching biomolecules
EP2140264A1 (en) * 2007-04-19 2010-01-06 3M Innovative Properties Company Methods of use of solid support material for binding biomolecules
JP5349838B2 (ja) * 2007-11-30 2013-11-20 和光純薬工業株式会社 ｓｍａｌｌＲＮＡの取得用担体、取得方法及び取得用試薬
WO2009137592A2 (en) * 2008-05-08 2009-11-12 3M Innovative Properties Company Surface-modified nanoparticles
KR100961280B1 (ko) 2008-05-21 2010-06-03 한국생명공학연구원 형광특성이 향상된 풀러렌-실리카 나노입자, 이의 제조방법및 이의 용도
US9211282B2 (en) 2009-09-25 2015-12-15 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
US10723628B2 (en) 2015-07-10 2020-07-28 Evonik Operations Gmbh SiO2 containing dispersion with high salt stability
WO2017009035A1 (de) 2015-07-10 2017-01-19 Evonik Degussa Gmbh Sio2 enthaltende dispersion mit hoher salzstabilität
WO2017009032A1 (de) 2015-07-10 2017-01-19 Evonik Degussa Gmbh Metalloxid enthaltende dispersion mit hoher salzstabilität
DK3368633T3 (da) 2015-10-26 2020-08-17 Evonik Operations Gmbh Fremgangsmåde til opnåelse af råolie ved anvendelse af en silicafluid
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
EP4087569A4 (en) 2020-01-10 2024-01-24 Trevi Therapeutics, Inc. METHODS OF ADMINISTRATION OF NALBUPHINE
WO2024137511A1 (en) * 2022-12-20 2024-06-27 The Regents Of The University Of Michigan High density microarrays and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE837243C (de) 1944-09-30 1952-04-21 Bayer Ag Schwebemittel fuer waessrige Suspensionen
US2801185A (en) 1952-05-16 1957-07-30 Du Pont Silica hydrosol powder
DE1467023A1 (de) * 1964-02-28 1969-01-23 Degussa Verfahren zur Inkorporierung von Wasser in feinst verteilter Kieselsaeure
US4680173A (en) * 1977-04-28 1987-07-14 Norman D. Burger Aerosol dispensing system
US4478876A (en) 1980-12-18 1984-10-23 General Electric Company Process of coating a substrate with an abrasion resistant ultraviolet curable composition
US4455205A (en) 1981-06-01 1984-06-19 General Electric Company UV Curable polysiloxane from colloidal silica, methacryloyl silane, diacrylate, resorcinol monobenzoate and photoinitiator
US4491508A (en) 1981-06-01 1985-01-01 General Electric Company Method of preparing curable coating composition from alcohol, colloidal silica, silylacrylate and multiacrylate monomer
US4486504A (en) 1982-03-19 1984-12-04 General Electric Company Solventless, ultraviolet radiation-curable silicone coating compositions
US4522958A (en) 1983-09-06 1985-06-11 Ppg Industries, Inc. High-solids coating composition for improved rheology control containing chemically modified inorganic microparticles
DE3333639A1 (de) * 1983-09-17 1985-03-28 Dynamit Nobel Ag Zubereitung von nitroestern fuer die koronartherapie
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US5037579A (en) 1990-02-12 1991-08-06 Nalco Chemical Company Hydrothermal process for producing zirconia sol
US5258225A (en) 1990-02-16 1993-11-02 General Electric Company Acrylic coated thermoplastic substrate
FR2666962B1 (fr) * 1990-09-26 1996-06-14 Oreal Composition antifongique sous forme de spray sec.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5182097A (en) 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
FR2677544B1 (fr) * 1991-06-14 1993-09-24 Oreal Composition cosmetique contenant un melange de nanopigments d'oxydes metalliques et de pigments melaniques.
DE4120760A1 (de) * 1991-06-24 1993-03-04 3 M Medica Gmbh Traegersysteme fuer arzneimittel
CA2421976C (en) 1991-12-12 2004-04-20 Glaxo Group Limited Medicaments
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
ATE128350T1 (de) 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
FR2698002B1 (fr) * 1992-11-13 1995-01-13 Oreal Composition cosmétique de maquillage contenant un fullerène ou un mélange de fullerènes comme agent pigmentant.
IL108416A (en) * 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
DK0731688T3 (da) 1993-12-02 2003-06-23 Abbott Lab Aerosol-lægemiddelformuleringer til anvendelse med CFC-frie drivmidler
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
IT1275955B1 (it) * 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
FR2746302B1 (fr) * 1996-03-20 1998-12-24 Oreal Compositions cosmetiques comprenant des nanopigments
US6054488A (en) 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
FR2759582A1 (fr) * 1997-02-14 1998-08-21 Oreal Composition deodorante
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
DE19811790A1 (de) * 1998-03-18 1999-09-23 Bayer Ag Nanopartikel enthaltende transparente Lackbindemittel mit verbesserter Verkratzungsbeständigkeit, ein Verfahren zur Herstellung sowie deren Verwendung
FR2781373B1 (fr) * 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
AU8761498A (en) 1998-07-30 2000-02-21 Minnesota Mining And Manufacturing Company Nanosize metal oxide particles for producing transparent metal oxide colloids and ceramers
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6258896B1 (en) * 1998-12-18 2001-07-10 3M Innovative Properties Company Dendritic polymer dispersants for hydrophobic particles in water-based systems
HUP0105445A2 (en) * 1999-02-03 2002-06-29 Fraunhofer Ges Forschung Compressed air inhaler for pulmonary application of liposomal powder aerosols and powder aerosols suitable therefor
US6238798B1 (en) * 1999-02-22 2001-05-29 3M Innovative Properties Company Ceramer composition and composite comprising free radically curable fluorochemical component
JP2003505537A (ja) 1999-07-20 2003-02-12 ザ、プロクター、エンド、ギャンブル、カンパニー 改良カプセル化油粒子
AU776770B2 (en) 1999-12-03 2004-09-23 Kuraray Co., Ltd. Dental or oralogic composition
FR2808704B1 (fr) * 2000-05-10 2002-08-16 Rhodia Chimie Sa Agents tensioactifs formes par des particules minerales de dimension nanometrique de surface modifiee
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
PL199420B1 (pl) 2000-10-09 2008-09-30 3M Innovative Properties Co Medyczne preparaty aerozolowe
US6586483B2 (en) 2001-01-08 2003-07-01 3M Innovative Properties Company Foam including surface-modified nanoparticles
US6467897B1 (en) 2001-01-08 2002-10-22 3M Innovative Properties Company Energy curable inks and other compositions incorporating surface modified, nanometer-sized particles
JP4293735B2 (ja) * 2001-01-19 2009-07-08 三栄源エフ・エフ・アイ株式会社 フラーレン誘導体およびそれからなる組成物
FR2830450B1 (fr) 2001-10-09 2004-02-06 Univ Pasteur Utilisation de dendrimeres dans une composition ophtalmique
US7001580B2 (en) * 2002-12-31 2006-02-21 3M Innovative Properties Company Emulsions including surface-modified organic molecules
US7129277B2 (en) * 2002-12-31 2006-10-31 3M Innovative Properties Company Emulsions including surface-modified inorganic nanoparticles
US7109247B2 (en) * 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles

Also Published As

Publication number Publication date
JP2006526624A (ja) 2006-11-24
CN1798549A (zh) 2006-07-05
WO2004108118A1 (en) 2004-12-16
EP1628645A1 (en) 2006-03-01
US20040241101A1 (en) 2004-12-02
KR20060038938A (ko) 2006-05-04
US7459146B2 (en) 2008-12-02
CN1798549B (zh) 2011-03-09

Similar Documents

Publication Publication Date Title
JP4680894B2 (ja) 安定化させた煙霧剤分散体
US7476694B2 (en) Methods of treating mammals with stabilized particle dispersions containing excipient surface-modified nanoparticles
KR101117846B1 (ko) 표면 개질 무기 나노입자를 포함하는 안정화된 입자 분산액
JP3056784B2 (ja) エアゾール医薬製剤
US9956170B2 (en) Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
JP5694643B2 (ja) 改善された流動性を示す組成物
EP2309984B1 (en) Method of making a dry powder pharmaceutical composition
EP2296628B1 (en) Process for manufacturing flowable powder drug compositions
WO2003059317A2 (en) Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110104

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110203

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140210

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees